2024 Scottsdale Headache Symposium

Since the inaugural meeting in 1970, the Scottsdale Headache Symposium® continues to be a successful venue for providing practical, clinical, evidence-based information on the diagnosis, management and treatment of patients with headache.

COURSE INSTRUCTIONS:

Live and virtual meeting attendees who joined us in Scottsdale have complimentary access to the recorded content within this course. AHS Members can login using their existing member credentials. All others can log into an existing Visitor account or create a new Visitor account. Once logged in, click "Take course" to access recorded content, complete the meeting evaluation, and claim CME.

INSTRUCTIONS FOR CLAIMING CME:

  • Click "Register/Take course" to begin
    • Members can login using your existing AHS member credentials
    • All others can login using an existing Visitor account or create a new Visitor account
  • Watch all recorded sessions for which credit* is sought
    • The recorded sessions will be available beginning Monday, November 18 through Saturday, May 31, 2025.
  • Complete the post-activity evaluation
    • The evaluation will be available until Monday, June 16, 2025.
  • For ABPN Self-Assessment credit, complete the short ABPN Self-Assessment quiz
  • Enter the number of CME credits being claimed per credit type
  • Download your certificate (be sure to select AMA credit [MDs/DOs] or Participation credit [all others] to access a certificate).

*Please note: The maximum number of credits is calculated based on attending all live and watching all recorded concurrent sessions. Some CME sessions are only offered live and will not be recorded.

Target Audience

The Symposium is designed for general practitioners, internists, pediatricians, neurologists, anesthesiologists, dentists, physical therapists, psychologists, psychiatrists, nurse practitioners, physician assistants, nurses, and other health professionals who treat headache. Education is presented in didactic, case-based, evidence-based, panel and demonstrative formats over the course of four days.

Learning Objectives

At the conclusion of the American Headache Society’s 2024 Scottsdale Headache Symposium, participants will be able to:

  • Apply knowledge of the diagnosis, epidemiology, and treatment of headache disorders in adults and children in clinical practice and research
  • Discuss controversies and evidence for using CGRP antagonists during pregnancy, in patients with vascular risk factors and as combination therapies
  • Incorporate non-pharmacologic treatments in the management of migraine
  • Select the appropriate neuroradiological investigations for various secondary headaches
Course summary
Available credit: 
  • 26.00 AAFP
  • 50.00 ABPN Self-Assessment
  • 50.00 AMA PRA Category 1 Credit™
  • 50.00 Participation
Course opens: 
11/18/2024
Course expires: 
06/17/2025
Cost:
$1,050.00

Disclosure Information

The planners and faculty for this activity did not have any relationships to disclose unless listed below. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.

PURPOSE/OBJECTIVE

At the conclusion of this program, learners will share that they feel better prepared to manage patients presenting with headache conditions by applying best practices in Headache Medicine retailed to the diagnosis, epidemiology, and treatment of headache disorders in adults and children in clinical practice and research, and will consider the controversies and evidence for using CGRP antagonists during pregnancy, in patients with vascular risk factors and as combination therapies. Learners will report their intention to incorporate non-pharmacologic treatments in the management of migraine & select the appropriate neuroradiological investigations for various secondary headaches.

ACCREDITATION STATEMENT

The American Headache Society® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The American Headache Society® designates this Other activity (live and recorded sessions) for a maximum of 50.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPN

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE 2024 SCOTTSDALE HEADACHE SYMPOSIUM AND HAS APPROVED THIS ACTIVITY AS PART OF A COMPREHENSIVE SELF-ASSESSMENT (SA) CME ACTIVITY, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF CONTINUING CERTIFICATION.

This activity awards up to 50 Category 1 CME which are approved as Self-Assessment credits. The approval period is for November 14, 2024 – June 16, 2025.

AAFP

The AAFP has reviewed 2024 Scottsdale Headache Symposium and deemed it acceptable for up to 26.00 Live AAFP Elective credit(s). Term of Approval is from 11/14/2024 to 11/17/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACOLOGY

This content has been reviewed for pharmacology hours and the calculated value is: 13.3 hours of pharmacology content.

INSTRUCTIONS FOR CLAIMING CME

  • Click "Register/Take course" to begin
  • Watch all recorded sessions for which credit* is sought
    • The recorded sessions will be available beginning Monday, November 18 through Saturday, May 31, 2025.
  • Complete the post-activity evaluation
    • The evaluation will be available until Monday, June 16, 2025.
  • For ABPN Self-Assessment credit, complete the short ABPN Self-Assessment quiz
  • Enter the number of CME credits being claimed per credit type
  • Download your certificate (be sure to select AMA credit [MDs/DOs] or Participation credit [all others] to access a certificate).

*Please note: The maximum number of credits is calculated based on attending all live and watching all recorded concurrent sessions. Some CME sessions are only offered live and will not be recorded.

FINANCIAL DISCLOSURES

The planners and faculty for this activity did not have any relationships to disclose unless listed here. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.

DISCLOSURE OF COMMERCIAL SUPPORT

The American Headache Society® received funding for this activity from the following organizations:

AbbVie Inc.
Axsome Therapeutics
Eli Lilly and Company
Lundbeck
Pfizer

The American Headache Society received an in-kind donation of migraine units (heads) for the Injection Training Session from the following organizations:

AbbVie Inc.

Available Credit

  • 26.00 AAFP
  • 50.00 ABPN Self-Assessment
  • 50.00 AMA PRA Category 1 Credit™
  • 50.00 Participation

Price

Cost:
$1,050.00
Please login or register to take this course.